assay, and 40.4, 70.0, and 68.9 percent, respectively, using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were seen for 8.9, 13.1, and 16.1 percent at doses of ...

The AHA/CDC statement makes the following recommendations for the use of hs-CRP in clinical practice: In terms of the clinical chemistry of the assay, hs-CRP is the marker of choice. Results of ...